Early-phase clinical trial results reported for invikafusp show a 59.3% disease control rate in advanced solid tumors, alongside a tolerability profile. The therapy is described as a dual T-cell agonist, aiming to enhance antitumor immune responses by stimulating T-cell activity through the drug’s designed immune mechanism. While the dataset is early, the results contribute to the expanding set of next-generation immune-stimulating agents seeking activity in settings where single-modality immunotherapy underperforms.